Establishment relocation and infrastructure changes
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Article 6.2.3 of RTS 11.03.02:21 sets the rule on establishment changes in a single sentence: any change of domicile or infrastructure at an establishment authorised by the authority requires prior application for approval. The provision does not distinguish between major and minor changes, and it creates no exemption. Any change of domicile or infrastructure falls within it.
Read with Article 6.2.2 a), under which the application file includes a floor plan and a location sketch, and with Article 5.3.2, under which the quality system must cover the activities actually carried out, a relocation touches three things at once: the establishment registration, the approved floor plan and the scope of the quality system.
The practical consequence is that relocation is a regulatory project with a lead time, not a facilities decision that is reported afterwards. The approval has to exist before the move, and the technical director carries a parallel reporting duty under a different provision.
2. Legal basis
The approval requirement, the documents that support it, the parallel reporting duty and the applicable fees are set out below.
| Level | Instrument | Reference | Publication date | Provision | Substance |
| Technical regulation | RTS 11.03.02:21 | Acuerdo No. 14-2022 | 2022-08-23 | Article 6.2.3 | Any change of domicile or infrastructure requires prior application for approval |
| Technical regulation | RTS 11.03.02:21 | Acuerdo No. 14-2022 | 2022-08-23 | Article 6.2.2 a) | Application file includes a floor plan showing total area and a location sketch |
| Technical regulation | RTS 11.03.02:21 | Acuerdo No. 14-2022 | 2022-08-23 | Article 6.2.4.1 e) | The technical director must report process and facility changes affecting device quality to the authority |
| Technical regulation | RTS 11.03.02:21 | Acuerdo No. 14-2022 | 2022-08-23 | Article 5.3.2 | The quality system must cover the activities actually carried out |
| Fees | Tarifario de la SRS (2025 edition) | Resolution of the Consejo de la SRS | 2025-10 | Articles 11.3.2, 11.4.3 | Relocation or remodelling of a device manufacturing or packaging laboratory USD 480.00; relocation of a device importer USD 72.00 |
| Fees | Tarifario de la SRS (2025 edition) | Resolution of the Consejo de la SRS | 2025-10 | Articles 11.6.1, 11.6.2 | Floor plan review for a new facility, relocation or remodelling USD 240.00; change of name or owner USD 48.00 |
The provisions cited in this article are Articles 5.3.2, 6.2.1 g), 6.2.2 a), 6.2.3 and 6.2.4.1 e) of RTS 11.03.02:21, Dispositivos Médicos. Requisitos para la Regulación Sanitaria de Dispositivos Médicos (Acuerdo No. 14-2022, Diario Oficial No. 156, Tomo No. 436, 2022-08-23), and Articles 11.3.2, 11.4.3, 11.6.1 and 11.6.2 of the Tarifario de la Superintendencia de Regulación Sanitaria (2025 edition, published on the SRS website in 2025-10).
Regulatory information verified as at 29 October 2026.
3. Expert insights
Insight one: prior is the operative word, and there is no route to regularise afterwards. Article 6.2.3 is worded so that approval must be applied for in advance. The provision leaves no space for retrospective ratification and sets no threshold of significance. The practical result is that even a move to a different unit in the same building requires an application first. Moving and then notifying is treated as an unapproved change, which places the establishment’s authorisation in question at the very moment when it also has to demonstrate continuity of its storage and distribution arrangements.
Insight two: a single relocation triggers more than one fee. Article 11.4.3 of the Tarifario prices the relocation of a device importer at USD 72.00, and Article 11.6.1 prices floor plan review for a new facility, a relocation or an infrastructure remodelling at USD 240.00. For a manufacturing establishment, Article 11.3.2 prices relocation or remodelling at USD 480.00. A pure importer and a manufacturing laboratory are therefore subject to different line items, and the budget has to be built according to the category of establishment rather than from a single template.
Insight three: the technical director’s reporting duty is a parallel second track. Article 6.2.4.1 e) requires the technical director to report process and facility changes that affect device quality to the authority. This is a different obligation from the prior approval in Article 6.2.3: the one is an ongoing reporting duty attached to a named individual, the other is a one-off authorisation attached to the establishment. A remodelling project has to run along both tracks, and completing the establishment application does not discharge the reporting duty, nor the reverse.
Insight four: infrastructure changes reach into the scope of the quality system. Article 5.3.2 requires the quality system to cover the activities the establishment actually carries out, and Article 6.2.1 g), item 1, requires the establishment to have facilities and technical personnel appropriate to the nature of the products and the activities to be performed. If a remodelling changes storage conditions, for example by adding cold storage, or changes the range of activities, for example by adding repackaging, then both the quality system documentation and the scope described in the system certificate must be updated in step.
4. Practical recommendations
- Submit the application under Article 6.2.3 before any relocation or remodelling, rather than moving first and notifying afterwards.
- Budget the relocation fee by establishment category, at USD 72.00 for an importer or USD 480.00 for a manufacturing laboratory, together with the USD 240.00 floor plan review fee.
- Have the technical director report process and facility changes affecting quality at the same time, under Article 6.2.4.1 e).
- Where the remodelling affects storage conditions or the range of activities, update the quality system documentation and the certificate scope in parallel.
- Update the floor plan showing total area and the location sketch so that they match the application file exactly.
- Write the relocation approval into the lease as a condition precedent to the lease taking effect.
5. Verification checklist
- □ Prior approval obtained for the relocation or remodelling
- □ Relocation fee and floor plan review fee calculated
- □ Technical director’s change report submitted
- □ Quality system documentation and certificate scope updated
- □ Floor plan and location sketch updated
- □ Lease agreement conditional on the approval
- □ Establishment registration details amended to reflect the new address
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Salvadoran market. Our team manages Ministry of Health (MINSAL) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us